Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fnins.2018.00254/full |